Compare NKSH & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | WHWK |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 197.2M |
| IPO Year | 1995 | N/A |
| Metric | NKSH | WHWK |
|---|---|---|
| Price | $36.80 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 56.3K | ★ 182.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $24.74 | $1.57 |
| 52 Week High | $40.00 | $4.40 |
| Indicator | NKSH | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 70.79 |
| Support Level | $27.59 | $1.85 |
| Resistance Level | $35.00 | N/A |
| Average True Range (ATR) | 1.43 | 0.28 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 0.56 | 90.00 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.